C
IDEXX Laboratories, Inc.
IDXX
$430.12
$1.090.25%
C
Hold
6/10/2024Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 6/10/2024 due to a decline in the total return index and efficiency index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 6/10/2024 due to a decline in the total return index and efficiency index.
C
Hold
3/14/2024Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 3/14/2024 due to an increase in the solvency index, efficiency index and total return index. Debt to equity declined from 0.8 to 0.65, the quick ratio increased from 0.88 to 1.03, and total capital increased 4.67% from $2.44B to $2.55B.
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 3/14/2024 due to an increase in the solvency index, efficiency index and total return index. Debt to equity declined from 0.8 to 0.65, the quick ratio increased from 0.88 to 1.03, and total capital increased 4.67% from $2.44B to $2.55B.
C
Hold
9/12/2023Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 9/12/2023 due to a decline in the total return index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 9/12/2023 due to a decline in the total return index.
C
Hold
8/2/2023Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 8/2/2023 due to a noticeable increase in the growth index, valuation index and solvency index. Debt to equity declined from 1.45 to 0.97, the quick ratio increased from 0.59 to 0.75, and operating cash flow increased 8.92% from $183.91M to $200.31M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 8/2/2023 due to a noticeable increase in the growth index, valuation index and solvency index. Debt to equity declined from 1.45 to 0.97, the quick ratio increased from 0.59 to 0.75, and operating cash flow increased 8.92% from $183.91M to $200.31M.
C
Hold
7/13/2023Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 7/13/2023 due to a decline in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 7/13/2023 due to a decline in the total return index and valuation index.
C
Hold
6/28/2023Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 6/28/2023 due to an increase in the total return index and volatility index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 6/28/2023 due to an increase in the total return index and volatility index.
C
Hold
6/13/2023Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 6/13/2023 due to a decline in the total return index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 6/13/2023 due to a decline in the total return index.
C
Hold
5/19/2023Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 5/19/2023 due to an increase in the volatility index and total return index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 5/19/2023 due to an increase in the volatility index and total return index.
C
Hold
7/21/2022Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 7/21/2022 due to a decline in the total return index, valuation index and volatility index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 7/21/2022 due to a decline in the total return index, valuation index and volatility index.
C
Hold
7/6/2022Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 7/6/2022 due to an increase in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to C+ from C on 7/6/2022 due to an increase in the total return index and valuation index.
C
Hold
5/23/2022Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 5/23/2022 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.37 to 1.87, and the quick ratio declined from 0.75 to 0.69.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 5/23/2022 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.37 to 1.87, and the quick ratio declined from 0.75 to 0.69.
C
Hold
2/23/2022Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 2/23/2022 due to a major decline in the total return index, volatility index and growth index. EBIT declined 11.85% from $225.96M to $199.19M, earnings per share declined from $2.03 to $1.8885, and total revenue declined 1.15% from $810.42M to $801.09M.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 2/23/2022 due to a major decline in the total return index, volatility index and growth index. EBIT declined 11.85% from $225.96M to $199.19M, earnings per share declined from $2.03 to $1.8885, and total revenue declined 1.15% from $810.42M to $801.09M.
B
Buy
10/7/2021Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 10/7/2021 due to a decline in the total return index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 10/7/2021 due to a decline in the total return index.
B
Buy
7/30/2021Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 7/30/2021 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 88.03% from $124.42M to $233.96M, total revenue increased 6.23% from $777.71M to $826.14M, and EBIT increased 4.7% from $247.62M to $259.25M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 7/30/2021 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 88.03% from $124.42M to $233.96M, total revenue increased 6.23% from $777.71M to $826.14M, and EBIT increased 4.7% from $247.62M to $259.25M.
B
Buy
7/13/2021Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 7/13/2021 due to a decline in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 7/13/2021 due to a decline in the total return index and valuation index.
B
Buy
6/25/2021Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 6/25/2021 due to an increase in the solvency index, total return index and valuation index. Debt to equity declined from 1.47 to 1.31.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 6/25/2021 due to an increase in the solvency index, total return index and valuation index. Debt to equity declined from 1.47 to 1.31.
B
Buy
4/21/2021Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C+ on 4/21/2021 due to a major increase in the total return index and volatility index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C+ on 4/21/2021 due to a major increase in the total return index and volatility index.
C
Hold
4/6/2021Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 4/6/2021 due to a decline in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 4/6/2021 due to a decline in the total return index and valuation index.
B
Buy
4/5/2021Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 4/5/2021 due to a major decline in the total return index and volatility index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 4/5/2021 due to a major decline in the total return index and volatility index.
B
Buy
3/19/2021Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 3/19/2021 due to a large increase in the total return index, volatility index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 3/19/2021 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
3/4/2021Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 3/4/2021 due to a large decline in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 3/4/2021 due to a large decline in the total return index and valuation index.
B
Buy
2/12/2021Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 2/12/2021 due to a large increase in the solvency index, total return index and growth index. Debt to equity declined from 2.09 to 1.47, the quick ratio increased from 1.06 to 1.3, and earnings per share increased from $1.69 to $2.0105.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 2/12/2021 due to a large increase in the solvency index, total return index and growth index. Debt to equity declined from 2.09 to 1.47, the quick ratio increased from 1.06 to 1.3, and earnings per share increased from $1.69 to $2.0105.
B
Buy
6/16/2020Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C+ on 6/16/2020 due to a major increase in the total return index, solvency index and growth index. Earnings per share increased from $1.0399 to $1.29, EBIT increased 11.85% from $129.03M to $144.33M, and total revenue increased 3.45% from $605.45M to $626.34M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C+ on 6/16/2020 due to a major increase in the total return index, solvency index and growth index. Earnings per share increased from $1.0399 to $1.29, EBIT increased 11.85% from $129.03M to $144.33M, and total revenue increased 3.45% from $605.45M to $626.34M.
C
Hold
3/19/2020Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 3/19/2020 due to a decline in the volatility index and total return index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 3/19/2020 due to a decline in the volatility index and total return index.
B
Buy
3/4/2020Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C+ on 3/4/2020 due to an increase in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C+ on 3/4/2020 due to an increase in the total return index and valuation index.
C
Hold
2/18/2020Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 2/18/2020 due to a large decline in the total return index, growth index and solvency index. Debt to equity increased from 4.65 to 5.65, EBIT declined 17.29% from $139.8M to $115.63M, and earnings per share declined from $1.24 to $1.0399.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B- on 2/18/2020 due to a large decline in the total return index, growth index and solvency index. Debt to equity increased from 4.65 to 5.65, EBIT declined 17.29% from $139.8M to $115.63M, and earnings per share declined from $1.24 to $1.0399.
B
Buy
10/30/2019Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 10/30/2019 due to a major decline in the valuation index and solvency index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 10/30/2019 due to a major decline in the valuation index and solvency index.
B
Buy
4/8/2019Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 4/8/2019 due to a noticeable increase in the total return index, valuation index and growth index. Operating cash flow increased 22.53% from $110.71M to $135.65M, and total revenue increased 0.72% from $545.45M to $549.39M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 4/8/2019 due to a noticeable increase in the total return index, valuation index and growth index. Operating cash flow increased 22.53% from $110.71M to $135.65M, and total revenue increased 0.72% from $545.45M to $549.39M.
B
Buy
1/17/2019Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 1/17/2019 due to a major decline in the volatility index, total return index and growth index. EBIT declined 17.59% from $145.59M to $119.98M, earnings per share declined from $1.23 to $1.05, and operating cash flow declined 6.83% from $118.83M to $110.71M.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 1/17/2019 due to a major decline in the volatility index, total return index and growth index. EBIT declined 17.59% from $145.59M to $119.98M, earnings per share declined from $1.23 to $1.05, and operating cash flow declined 6.83% from $118.83M to $110.71M.
B
Buy
10/11/2018Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 10/11/2018 due to a large decline in the total return index, valuation index and solvency index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 10/11/2018 due to a large decline in the total return index, valuation index and solvency index.
B
Buy
5/8/2018Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 5/8/2018 due to a significant increase in the total return index, volatility index and efficiency index. Net income increased 133.82% from $38.26M to $89.45M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 5/8/2018 due to a significant increase in the total return index, volatility index and efficiency index. Net income increased 133.82% from $38.26M to $89.45M.
B
Buy
8/18/2017Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 8/18/2017 due to a significant decline in the total return index and volatility index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 8/18/2017 due to a significant decline in the total return index and volatility index.
B
Buy
8/3/2017Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 8/3/2017 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 252.34% from $31.27M to $110.19M, EBIT increased 32.87% from $92.24M to $122.56M, and earnings per share increased from $0.77 to $0.95.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 8/3/2017 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 252.34% from $31.27M to $110.19M, EBIT increased 32.87% from $92.24M to $122.56M, and earnings per share increased from $0.77 to $0.95.
B
Buy
7/21/2017Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 7/21/2017 due to a noticeable decline in the volatility index, total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 7/21/2017 due to a noticeable decline in the volatility index, total return index and valuation index.
B
Buy
7/5/2017Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 7/5/2017 due to a large increase in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 7/5/2017 due to a large increase in the total return index and valuation index.
B
Buy
6/12/2017Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 6/12/2017 due to a decline in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 6/12/2017 due to a decline in the total return index and valuation index.
B
Buy
4/28/2017Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 4/28/2017 due to a noticeable increase in the volatility index, total return index and growth index. Earnings per share increased from $0.5703 to $0.77, EBIT increased 10.04% from $83.83M to $92.24M, and total revenue increased 4.29% from $443M to $462.02M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 4/28/2017 due to a noticeable increase in the volatility index, total return index and growth index. Earnings per share increased from $0.5703 to $0.77, EBIT increased 10.04% from $83.83M to $92.24M, and total revenue increased 4.29% from $443M to $462.02M.
B
Buy
2/21/2017Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 2/21/2017 due to a major increase in the solvency index, valuation index and growth index. Debt to equity declined from 19.82 to -11.11.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 2/21/2017 due to a major increase in the solvency index, valuation index and growth index. Debt to equity declined from 19.82 to -11.11.
B
Buy
2/13/2017Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 2/13/2017 due to a major decline in the valuation index, solvency index and growth index. Debt to equity increased from -133.82 to 19.82, earnings per share declined from $0.74 to $0.62, and EBIT declined 15.08% from $104.16M to $88.46M.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 2/13/2017 due to a major decline in the valuation index, solvency index and growth index. Debt to equity increased from -133.82 to 19.82, earnings per share declined from $0.74 to $0.62, and EBIT declined 15.08% from $104.16M to $88.46M.
B
Buy
10/31/2016Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 10/31/2016 due to a decline in the total return index, valuation index and volatility index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 10/31/2016 due to a decline in the total return index, valuation index and volatility index.
B
Buy
8/11/2016Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 8/11/2016 due to a noticeable increase in the growth index, total return index and solvency index. Debt to equity declined from -16.53 to -133.82, operating cash flow increased 377.55% from $23.23M to $110.92M, and earnings per share increased from $0.51 to $0.74.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 8/11/2016 due to a noticeable increase in the growth index, total return index and solvency index. Debt to equity declined from -16.53 to -133.82, operating cash flow increased 377.55% from $23.23M to $110.92M, and earnings per share increased from $0.51 to $0.74.
B
Buy
5/31/2016Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 5/31/2016 due to a noticeable decline in the total return index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 5/31/2016 due to a noticeable decline in the total return index and valuation index.
B
Buy
5/16/2016Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 5/16/2016 due to a significant increase in the total return index, volatility index and solvency index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 5/16/2016 due to a significant increase in the total return index, volatility index and solvency index.
B
Buy
4/29/2016Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 4/29/2016 due to a major increase in the growth index, volatility index and total return index. EBIT increased 10.29% from $66.91M to $73.79M, earnings per share increased from $0.4792 to $0.51, and total revenue increased 4.47% from $399.69M to $417.55M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 4/29/2016 due to a major increase in the growth index, volatility index and total return index. EBIT increased 10.29% from $66.91M to $73.79M, earnings per share increased from $0.4792 to $0.51, and total revenue increased 4.47% from $399.69M to $417.55M.
B
Buy
3/11/2016Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from -29.36 to -13.91, and the quick ratio declined from 0.67 to 0.63.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B- from B on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from -29.36 to -13.91, and the quick ratio declined from 0.67 to 0.63.
B
Buy
10/30/2015Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 10/30/2015 due to a significant increase in the solvency index, valuation index and volatility index. Debt to equity declined from 129.54 to -29.36.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B from B- on 10/30/2015 due to a significant increase in the solvency index, valuation index and volatility index. Debt to equity declined from 129.54 to -29.36.
B
Buy
10/16/2015Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C on 10/16/2015 due to a significant increase in the total return index, volatility index and growth index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B- from C on 10/16/2015 due to a significant increase in the total return index, volatility index and growth index.
C
Hold
10/2/2015Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 10/2/2015 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 30.85 to 129.54.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C from C+ on 10/2/2015 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 30.85 to 129.54.
C
Hold
4/30/2015Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B on 4/30/2015 due to a substantial decline in the total return index, solvency index and volatility index. Debt to equity increased from 7.65 to 30.85.
IDEXX Laboratories, Inc. (IDXX) was downgraded to C+ from B on 4/30/2015 due to a substantial decline in the total return index, solvency index and volatility index. Debt to equity increased from 7.65 to 30.85.
B
Buy
2/19/2015Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 2/19/2015 due to a significant decline in the growth index, solvency index and valuation index. Debt to equity increased from 3.16 to 7.65, operating cash flow declined 70.72% from $93.26M to $27.3M, and EBIT declined 54.5% from $76.49M to $34.8M.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 2/19/2015 due to a significant decline in the growth index, solvency index and valuation index. Debt to equity increased from 3.16 to 7.65, operating cash flow declined 70.72% from $93.26M to $27.3M, and EBIT declined 54.5% from $76.49M to $34.8M.
B
Buy
12/22/2014Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 12/22/2014 due to a substantial increase in the total return index and volatility index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 12/22/2014 due to a substantial increase in the total return index and volatility index.
B
Buy
10/27/2014Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 10/27/2014 due to a noticeable decline in the growth index, solvency index and efficiency index. Debt to equity increased from 1.18 to 3.16, net income declined 8.87% from $57.22M to $52.14M, and the quick ratio declined from 0.79 to 0.72.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 10/27/2014 due to a noticeable decline in the growth index, solvency index and efficiency index. Debt to equity increased from 1.18 to 3.16, net income declined 8.87% from $57.22M to $52.14M, and the quick ratio declined from 0.79 to 0.72.
B
Buy
8/22/2014Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B+ from A- on 8/22/2014 due to a decline in the total return index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B+ from A- on 8/22/2014 due to a decline in the total return index.
A
Buy
8/7/2014Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to A- from B+ on 8/7/2014 due to an increase in the volatility index and valuation index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to A- from B+ on 8/7/2014 due to an increase in the volatility index and valuation index.
B
Buy
7/25/2014Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 7/25/2014 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 143.93% from $33.52M to $81.76M, earnings per share increased from $0.89 to $1.1, and EBIT increased 18.81% from $70.05M to $83.22M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 7/25/2014 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 143.93% from $33.52M to $81.76M, earnings per share increased from $0.89 to $1.1, and EBIT increased 18.81% from $70.05M to $83.22M.
B
Buy
7/3/2014Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 7/3/2014 due to a decline in the valuation index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 7/3/2014 due to a decline in the valuation index.
B
Buy
6/11/2014Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 6/11/2014 due to an increase in the total return index.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 6/11/2014 due to an increase in the total return index.
B
Buy
5/27/2014Downgrade
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 5/27/2014 due to a decline in the valuation index and total return index.
IDEXX Laboratories, Inc. (IDXX) was downgraded to B from B+ on 5/27/2014 due to a decline in the valuation index and total return index.
B
Buy
5/7/2014Upgraded
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 5/7/2014 due to an increase in the efficiency index and growth index. EBIT increased 14.22% from $61.33M to $70.05M, earnings per share increased from $0.8189 to $0.89, and net income increased 7.69% from $43.26M to $46.59M.
IDEXX Laboratories, Inc. (IDXX) was upgraded to B+ from B on 5/7/2014 due to an increase in the efficiency index and growth index. EBIT increased 14.22% from $61.33M to $70.05M, earnings per share increased from $0.8189 to $0.89, and net income increased 7.69% from $43.26M to $46.59M.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
